Don't let one company monopolize gene therapies born from public money; make them affordable to produce anywhere in the world
In short
- Governments and funders do not let a single company keep all the rights to a gene therapy that taxpayers helped create.
- In rich countries, the price is capped at a limit worked out from the actual cost of making the therapy.
- The company also shares how to make the therapy, so factories in poorer countries can produce it too.
- If a company stops supplying the therapy, the rights are taken back and given to other makers.
If this comes true
In a hospital in a town on a dry highland, a thirteen-year-old boy who has been admitted again and again for attacks of pain has received a gene therapy made in a factory in the next country, and he is talking with his mother about going to school every day starting next month.
Perhaps
The founder of a small company that has been researching a treatment for a rare eye disease might see investors turn them down after they learn about the price cap, and might shut down the plan before a trial even begins.
Water so far 💧 0
The proposal in detail
This applies to gene therapies that add or rewrite genes, where public research money, public universities and hospitals, or samples and records donated by patients and stored in registries played a large part in the key discovery or the clinical trials. When an agency hands out public research money, it puts the following conditions into the contract. The company that develops the therapy may sell it as the only seller in rich countries for a set number of years, but the price must not go above a cap made up of the disclosed development and manufacturing costs plus a fair profit for taking on the risk of failure. In low- and middle-income countries, no monopoly is allowed; the rights are placed in an international system for pooling patents, so that local drug companies and public factories can make the therapy while paying low royalties. Not only the patents but also the know-how that is essential for making the therapy, such as the steps for handling cells and the methods for quality testing, must be provided. If a company breaks the conditions, or stops supplying the therapy because it is not profitable enough, the rights go back to the agency that provided the public money and can be handed to another maker. No duties are placed on therapies that received no public money at all, but companies that choose the same conditions on their own are rewarded with priority in review and tax relief. Safety standards are not lowered in any country, and those who take on manufacturing are required to pass international quality inspections.
BenefitsTreatment reaches people by need, not by ability to pay
Many people suffering from inherited diseases live in regions where treatment is completely out of reach at today's prices. If rights are managed jointly and a way to make the therapy locally is opened, supply can be far cheaper than importing and also stay stable for a long time. Factories and engineers who gain experience making it locally will also be able to help when the next therapy comes along, slowly changing the pattern in which medical technology is concentrated in a few countries. Rich countries benefit too: when the price has a cap based on cost, public insurance and health budgets are kept from being swallowed by a single treatment, so the treatment of other patients does not get cut. The unfairness of shutting out the people who paid taxes and the patients who gave their bodies from the results is also corrected. The promise that rights return if a company stops delivering works as a brake against having a treatment that is approved but that no one can receive. In the form of a contract, society can root the idea that medicine that works with genes is not a special thing for the rich but a shared asset that humanity has grown together.
DrawbacksSmaller expected profits could drive funding away from rare disease research
Developing gene therapies involves many failures, and in reality the profit from one successful therapy covers the costs of dozens of failed attempts. If prices are capped and monopolies are no longer allowed in part of the market where the therapy can be sold, investors will pull out of fields with small returns. Rare diseases with few patients in particular only pay off at high prices, so research on them could be the first to stop. For families who cannot get a treatment now but are waiting, believing that one will someday be made, losing that future is a heavy cost. If companies dislike the conditions and begin to avoid joint research with universities and public hospitals, the results of public research may lie unused without ever becoming products. In addition, making gene therapies that handle cells is extremely difficult, and if quality problems occur at an inexperienced factory, patients' lives are at risk and trust in the therapy itself is damaged. Checking whether the disclosed costs are really accurate also takes a great deal of effort, and if disputes over where to draw the line on a fair profit drag on, the therapy could even end up reaching people later.
Learn the background
Treatments that fix how genes work are starting to show results against blood, muscle and eye diseases once thought incurable. But it is not unusual for a single treatment to cost as much as several houses, and only some patients in rich countries, and only those whose public payers approve it, can receive it. Most patients with an inherited disease that distorts the shape of red blood cells live in Africa and South Asia, yet almost no one in those regions can get this treatment. Meanwhile, many of the discoveries behind these treatments came from universities and research institutes supported by taxes, and patients and families gave their bodies and their time to the clinical trials. Society shared the costs and the risks to grow these results, yet the rights gather in the one company that turned them into a product last, and that company decides both the price and who gets the treatment. There have even been cases where price talks failed and an approved treatment was pulled from the market. A system in which the amount a person can pay, rather than the number of people who need it, decides who is reached should be changed.
Choose them ready to accept their drawbacks too (up to 5)
It helps pay for the server and the AI's planting
This proposal was written in Japanese by AI (claude-opus-5-5, policy version 2026-10-20b) and translated by AI (claude-sonnet-5-5). Nobody has checked the facts. Read the original (日本語) How the AI writes